Radionuclide drug conjugates (RDCs) are emerging as transformative agents that merge diagnosis and therapy into a single clinical workflow, according to a comprehensive review published in the Medical Journal of Peking Union Medical College Hospital. By coupling radioactive isotopes with targeting moieties such as antibodies, peptides, or small molecules, RDCs enable precise tumor localization, high diagnostic sensitivity, and effective localized radiotherapy, offering a theranostic approach that could redefine cancer management.
The review, conducted by researchers at Peking Union Medical College Hospital and available at https://xhyxzz.pumch.cn/article/doi/10.12290/xhyxzz.2024-0577, analyzes 15 years of progress in RDC research, covering classifications, clinical development trends, and supportive policy frameworks. The study notes an expanding number of clinical trials, new therapeutic targets, and national-level guidance that are shaping the next generation of precision radiopharmaceuticals.
Structurally, RDCs are categorized into antibody-, peptide-, and small-molecule-based conjugates, each with distinct pharmacological advantages. The review highlights the rise of cyclic peptide conjugates, which exhibit low toxicity and high tumor selectivity. Policy reforms, including technical guidelines issued by regulatory agencies since 2020, have standardized clinical evaluation, non-clinical research, and radiochemical quality control, creating a more predictable environment for innovation.
“RDCs represent the only class of therapeutics capable of achieving true integration of diagnosis and treatment,” said Prof. Hongyun Wang, senior author of the review. “Despite challenges in radiochemical synthesis, stability, and regulatory alignment, we are witnessing unprecedented enthusiasm and cross-disciplinary collaboration in this field. With continued innovation in targeting ligands and isotope design, RDCs will redefine how we approach tumor detection, treatment monitoring, and personalized therapy.”
RDCs hold vast potential to transform cancer management by enabling simultaneous imaging, treatment, and response monitoring within a single platform. As aging populations and cancer incidence continue to rise, demand for next-generation radiopharmaceuticals will grow. The review underscores the need for stronger innovation capacity, improved isotope supply chains, and streamlined approval processes to support RDC translation from laboratory to clinic. Through coordinated scientific, industrial, and regulatory efforts, RDCs are expected to become a central component of future oncology care, offering patients more accurate diagnoses and safer, more effective treatment pathways.
The research was supported by Capital's Funds for Health Improvement and Research (2022-2Z-4018) and National High-Level Hospital Clinical Research Funding (2022-PUMCH-B-118). The study was published in the Medical Journal of Peking Union Medical College Hospital, which is affiliated with Chuanlink Innovations, as noted at http://chuanlink-innovations.com.
